Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GENOCEA BIOSCIENCES, INC.GNCA · Entity 12635 | Director | June 18, 2020 | June 19, 2020 |
| Invivyd, Inc.ADGI · Entity 721 | Director | June 22, 2022 | June 24, 2022 |
| PepGen Inc.PEPG · Entity 6253 | Director | June 18, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GENOCEA BIOSCIENCES, INC.
Report date June 18, 2020 · Filed June 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.22 · Expires 2030-06-18 | Direct | 15,000 |
Reported balance
After 2020-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-18 · Grant · Acquired 15,000 · Balance 15,000 F1: The option vests 100% on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests 100% on the first anniversary of the grant date.
Invivyd, Inc.
Report date June 22, 2022 · Filed June 24, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.09 · Expires 2032-06-21 | Direct | 75,000 |
Reported balance
After 2022-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-22 · Grant · Acquired 75,000 · Balance 75,000 F1: This option was granted on June 22, 2022 and vests in full on the earlier of (i) June 22, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to continued service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 22, 2022 and vests in full on the earlier of (i) June 22, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to continued service through the vesting date.
PepGen Inc.
Report date June 18, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.79 · Expires 2036-06-17 | Direct | 34,000 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 34,000 · Balance 34,000 F1: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Entasis Therapeutics Holdings Inc.
Report date July 07, 2022 · Filed July 11, 2022
Section 16 reporting ended · disclosed 2022-07-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-07-07 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2022-07-07 · Other · Disposed 22,000 · Balance 0 F1: Disposed of to Innoviva Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated May 23, 2022, by and between the Issuer, Innoviva, Inc. ("Innoviva"), and Merger Sub (the "Merger Agreement"), completed a tender offer to acquire all of the issued and outstanding shares of the Issuer's common stock (other than those shares owned by Innoviva and Merger Sub) at a purchase price of $2.20 per share (the "Offer Price"). |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-07-11 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2022-07-11 · Disposition to issuer · Disposed 27,500 · Balance 0 F2: Each Issuer restricted stock unit that was outstanding immediately prior to the date and time at which the merger of Merger Sub with and into the Issuer (the "Merger") became effective (the "Effective Time") was deemed vested and converted into the right to receive a cash payment equal to the per share Merger consideration of $2.20. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.44 | Direct | 0 |
Reported balance
After 2022-07-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-07-11 · Other · Disposed 12,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.98 | Direct | 0 |
Reported balance
After 2022-07-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-07-11 · Other · Disposed 11,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of to Innoviva Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated May 23, 2022, by and between the Issuer, Innoviva, Inc. ("Innoviva"), and Merger Sub (the "Merger Agreement"), completed a tender offer to acquire all of the issued and outstanding shares of the Issuer's common stock (other than those shares owned by Innoviva and Merger Sub) at a purchase price of $2.20 per share (the "Offer Price").
F2: Each Issuer restricted stock unit that was outstanding immediately prior to the date and time at which the merger of Merger Sub with and into the Issuer (the "Merger") became effective (the "Effective Time") was deemed vested and converted into the right to receive a cash payment equal to the per share Merger consideration of $2.20.
F3: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 22, 2026 20:10 UTC | PepGen Inc. PEPG · Entity 6253 | GrantStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001835597-26-000032 · form4.xml · derivative · entry 1 Mayer Howard · CIK 0001699610 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2036-06-17 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 10:56 UTC | PepGen Inc. PEPG · Entity 6253 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0001127602-25-016932 · form4.xml · derivative · entry 1 Mayer Howard · CIK 0001699610 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:04 UTC | PepGen Inc. PEPG · Entity 6253 | GrantStock Option (Right to Buy) · Derivative | 8,667 | $0.00 Strike: $16.80 | $0.00 |
DisclosureSEC source: 0001127602-24-019117 · form4.xml · derivative · entry 1 Mayer Howard · CIK 0001699610 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,667 Underlying: Common Stock · 8,667 shares Expires 2034-06-19 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the individual ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. Read SEC document |
| November 10, 2023 Filed Nov 15, 2023 00:11 UTC | PepGen Inc. PEPG · Entity 6253 | GrantStock Option (Right to Buy) · Derivative | 22,686 | $0.00 Strike: $3.86 | $0.00 |
DisclosureSEC source: 0001127602-23-027405 · form4.xml · derivative · entry 1 Mayer Howard · CIK 0001699610 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,686 Underlying: Common Stock · 22,686 shares Expires 2033-11-09 F1 · derivative.exercise_date: This option shall vest as follows: One-third (1/3) on November 10, 2024 and the remainder vesting in twenty-four (24) equal monthly installments, subject to the option recipient's continued service or employment with the Company on each applicable vesting date. Read SEC document |
| July 11, 2022 Filed Jul 11, 2022 20:06 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | OtherStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001104659-22-078796 · tm2220760-5_4seq1.xml · derivative · entry 4 Mayer Howard · CIK 0001699610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,000 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. Read SEC document |
| July 11, 2022 Filed Jul 11, 2022 20:06 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | OtherStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001104659-22-078796 · tm2220760-5_4seq1.xml · derivative · entry 3 Mayer Howard · CIK 0001699610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. Read SEC document |
| July 11, 2022 Filed Jul 11, 2022 20:06 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | Disposition to issuerCommon Stock | 27,500 | $2.20 | $60,500.00 |
DisclosureSEC source: 0001104659-22-078796 · tm2220760-5_4seq1.xml · nonDerivative · entry 2 Mayer Howard · CIK 0001699610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · shares: Each Issuer restricted stock unit that was outstanding immediately prior to the date and time at which the merger of Merger Sub with and into the Issuer (the "Merger") became effective (the "Effective Time") was deemed vested and converted into the right to receive a cash payment equal to the per share Merger consideration of $2.20. F2 · price: Each Issuer restricted stock unit that was outstanding immediately prior to the date and time at which the merger of Merger Sub with and into the Issuer (the "Merger") became effective (the "Effective Time") was deemed vested and converted into the right to receive a cash payment equal to the per share Merger consideration of $2.20. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 20:06 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | OtherCommon Stock | 22,000 | $2.20 | $48,400.00 |
DisclosureSEC source: 0001104659-22-078796 · tm2220760-5_4seq1.xml · nonDerivative · entry 1 Mayer Howard · CIK 0001699610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of to Innoviva Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated May 23, 2022, by and between the Issuer, Innoviva, Inc. ("Innoviva"), and Merger Sub (the "Merger Agreement"), completed a tender offer to acquire all of the issued and outstanding shares of the Issuer's common stock (other than those shares owned by Innoviva and Merger Sub) at a purchase price of $2.20 per share (the "Offer Price"). F1 · price: Disposed of to Innoviva Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated May 23, 2022, by and between the Issuer, Innoviva, Inc. ("Innoviva"), and Merger Sub (the "Merger Agreement"), completed a tender offer to acquire all of the issued and outstanding shares of the Issuer's common stock (other than those shares owned by Innoviva and Merger Sub) at a purchase price of $2.20 per share (the "Offer Price"). Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 20:36 UTC | Invivyd, Inc. ADGI · Entity 721 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $3.09 | $0.00 |
DisclosureSEC source: 0000899243-22-024015 · doc4.xml · derivative · entry 1 Mayer Howard · CIK 0001699610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-06-21 F1 · derivative.exercise_date: This option was granted on June 22, 2022 and vests in full on the earlier of (i) June 22, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to continued service through the vesting date. Read SEC document |
| January 18, 2022 Filed Jan 19, 2022 21:03 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantCommon Stock | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-005419 · tm223320-7_4seq1.xml · nonDerivative · entry 1 Mayer Howard · CIK 0001699610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,500 F1 · shares: This award vests in full on the first anniversary of the date of grant, subject to the reporting person's continued service as a director of the Company. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 23:59 UTC | Invivyd, Inc. ADGI · Entity 721 | GrantStock Option (Right to Buy) · Derivative | 35,593 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-050492 · doc4.xml · derivative · entry 1 Mayer Howard · CIK 0001699610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,593 Underlying: Common Stock · 35,593 shares Expires 2031-08-04 F1 · derivative.exercise_date: One third (1/3) of the option shall vest on August 5, 2022, and thereafter, the remainder of the option shall vest in 24 equal monthly installments on the 5th day of each month, subject to the Reporting Person's continuous service on each vesting date. Read SEC document |
| July 16, 2021 Filed Feb 15, 2022 21:03 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantStock Option (Right to Buy) · Derivative | 12,500 | Not disclosed Strike: $2.44 | Not disclosed |
DisclosureSEC source: 0001104659-22-023776 · tm226724-6_4seq1.xml · derivative · entry 2 Mayer Howard · CIK 0001699610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2031-07-15 F3 · price: Seventy-three (73%) of this award will vest on July 16, 2022, and one-thirteenth of the remaining shares subject to the option will vest monthly following July 16, 2022, subject to the Reporting Person's continuing to provide service through each such date. F3 · derivative.exercise_date: Seventy-three (73%) of this award will vest on July 16, 2022, and one-thirteenth of the remaining shares subject to the option will vest monthly following July 16, 2022, subject to the Reporting Person's continuing to provide service through each such date. Read SEC document |
| July 16, 2021 Filed Feb 15, 2022 21:03 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $6.44 | Not disclosed |
DisclosureSEC source: 0001104659-22-023776 · tm226724-6_4seq1.xml · derivative · entry 1 Mayer Howard · CIK 0001699610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2029-08-04 F2 · price: On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 shares of issuer's common stock granted to the Reporting Person on August 5, 2019. In exchange, the Reporting Person received a replacement option for 12,500 shares of issuer's common stock, having an exercise price of $2.44 per share. F1 · derivative.exercise_date: The option provided for vesting as follows: The shares subject to this option will vest in equal monthly installments over the three years following the date of grant, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 14:36 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantCommon Stock | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-045915 · tm2111994-4_4seq1.xml · nonDerivative · entry 1 Mayer Howard · CIK 0001699610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 20:13 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001457612-20-000103 · wf-form4_159259760895277.xml · derivative · entry 1 Mayer Howard · CIK 0001699610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-18 F1 · derivative.exercise_date: The option vests 100% on the first anniversary of the grant date. Read SEC document |
| June 10, 2020 Filed Oct 6, 2020 20:32 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001104659-20-112657 · a4.xml · derivative · entry 1 Mayer Howard · CIK 0001699610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2030-06-09 F1 · derivative.exercise_date: The shares subject to this option will vest in equal monthly installments over the 12 months following the date of grant, provided that the option will in any case be fully vested on the date of the next annual stockholder meeting, subject to the Reporting Persons's continued service through each such vesting date. Read SEC document |
| August 05, 2019 Filed Aug 6, 2019 20:10 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.44 | $0.00 |
DisclosureSEC source: 0001104659-19-044300 · a4.xml · derivative · entry 1 Mayer Howard · CIK 0001699610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-08-04 F1 · derivative.exercise_date: The shares subject to this option will vest in equal monthly installments over the three years following the date of grant, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| July 18, 2019 Filed Jul 19, 2019 20:11 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 5,625 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001457612-19-000114 · wf-form4_156356705552014.xml · derivative · entry 1 Mayer Howard · CIK 0001699610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,625 Underlying: Common Stock · 5,625 shares Expires 2029-07-18 F1 · derivative.exercise_date: The option vests 100% on the first anniversary of the grant date. Read SEC document |
| June 21, 2018 Filed Jun 26, 2018 00:08 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001457612-18-000070 · wf-form4_152997169151474.xml · derivative · entry 1 Mayer Howard · CIK 0001699610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-06-21 F1 · derivative.exercise_date: The option vests 100% on the first anniversary of the grant date. Read SEC document |
| March 06, 2017 Filed Mar 7, 2017 21:01 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001699610-17-000004 · wf-form4_148892049729106.xml · derivative · entry 1 Mayer Howard · CIK 0001699610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-03-06 F1 · derivative.exercise_date: The option vests annually in equal installments over a three-year period beginning on the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.